Loading
companiesCompany
Inhibrx Biosciences
Inhibrx Biosciences is a San Diego antibody company testing two cancer drugs: ozekibart, which triggers a self-destruct receptor on tumour cells in bone cancers such as Ewing sarcoma, and an OX40 antibody that boosts immune cells. Sanofi bought its sister lung disease drug in 2024.
Overview
Inhibrx Biosciences is a La Jolla, California clinical-stage company that engineers multivalent biologics. Ozekibart (INBRX-109) is a tetravalent DR5 (death receptor 5) agonist designed to induce tumour-selective programmed cell death and is enrolling patients with Ewing sarcoma in phase 1; INBRX-106 is a hexavalent OX40 agonist designed to promote receptor hyperclustering, in phase 1/2 and phase 2/3 trials. In January 2024 the predecessor Inhibrx, Inc. agreed to sell INBRX-101, a recombinant alpha-1 antitrypsin for alpha-1 antitrypsin deficiency, to Sanofi for 30 US dollars per share in cash plus a 5 US dollar contingent value right (about 2.2 billion US dollars aggregate value). Immediately before that merger closed on 30 May 2024, the non-101 assets (INBRX-105, INBRX-106, INBRX-109) were spun out into Inhibrx Biosciences, which received 200 million US dollars in cash, has Sanofi as an 8 percent holder and trades on Nasdaq as INBX.
Headquarters
La Jolla, CA, US
Scorecard
All companies#397of 1244 companies, score 9
- phase 3 +3
- modalities +2
- registry trials +4
0 approved, 1 in phase 3, 0 earlier, 0 targets, 4 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Predecessor Inhibrx, Inc. sold its INBRX-101 (alpha-1 antitrypsin) asset to Sanofi for about 2.2 billion US dollars aggregate value; oncology assets were spun out into Inhibrx Biosciences, capitalised with 200 million US dollars from Sanofi; completed 30 May 2024 | 2024 | $2.2B | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · INBX
Stage
Public
Website
Phase 3monoclonal antibody
INBRX-106 is an experimental monoclonal antibody from Inhibrx Biosciences in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.
Notes
top- Chondrosarcoma and INBRX-105 status not confirmed from the fetched pipeline page. Inhibrx's own IPO (2020) not sourced.
cancers
fronts
technologies
drugs
Phase 3monoclonal antibody